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Background:  Hypovitaminosis D is endemic worldwide. With the discovery of extra 
skeletal receptors for 1,25-dihydroxyvitamin D, the influence of vitamin D (25(OH)D3) 
deficiency has been investigated in metabolic diseases. In South Africa, little is known 
about 25(OH)D3 status. 
Aim: To investigate the 25(OH)D3  status in patients in Johannesburg, and to assess for any 
correlation between 25(OH)D3 , metabolic diseases and patient demographics and seasonal 
variation. 
Methods: A retrospective study of 1000 patients attending a northern suburb practice in 
Johannesburg was performed. Serum 25(OH)D3 levels, demographics and metabolic data 
were collected. 
Results: The mean 25(OH)D3 level was 24.45ng/ml and 74.3% were vitamin D deficient. 
There was no difference in mean 25(OH)D3 levels between age or gender groups. The 
lowest mean 25(OH)D3 was in the Indian race (p=0.001), HOMA-IR >2 (p=0.001), fasting 
glucose >7 (p=0.016) and highest was measured during the summer (p=0.001). There was 
a significant correlation between 25(OH)D3 level and cholesterol (p=0.001), however no 
correlation was found with hypertension or diabetes. 
Conclusion: This study reports a high incidence of hypovitaminosis D especially among 
Indians. In this study there was no correlation between hypovitaminosis D and metabolic 
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1. Chapter 1.  Introduction and Literature Review 
1.1. Introduction 
Vitamin D, unlike the name suggests, is in fact not a vitamin, but rather a hormone. 
McCollum et al discovered Vitamin D in 1922, and termed it ‘D’ because it was the fourth 
known ‘vitamin’(1).Vitamin D exists in two forms, vitamin D2 (25-hydroxylated 
ergocalciferol) and vitamin D3 (cholecalciferol). Cholecalciferol is a prohormone which is 
produced in the skin through ultraviolet radiation. It is a lipid soluble compound with a 
four ringed cholesterol backbone. This hormone form of vitamin D3 acts through a nuclear 
receptor to carry out its functions (2). 
1.2. Metabolism of Vitamin D 
Humans derive vitamin D through exposure to sunlight (vitamin D3), from their diet 
(vitamin D2), as well as from dietary supplements (vitamin D2 and/or D3).  Since very few 
natural foods contain vitamin D some dietary sources are now fortified with vitamin D, 
such as fortified dairy products. One of the few foods containing natural vitamin D is oily 
fish. Ultraviolet B (solar) radiation penetrates the skin and converts 7-dehydrocholesterol      
(a derivative of cholesterol) to previtamin D3 (precholecalciferol). This then undergoes 
conversion to vitamin D3, which is the natural form of vitamin D in the skin. 
Vitamin D2 is produced by irradiation of ergosterol. In the liver, vitamin D3 and D2 are 
metabolised to 25-hydroxyvitamin D (25(OH)D3), which is the stored, metabolically inert 
form of vitamin D, and is used to determine a patient’s vitamin D status. To activate 
25(OH)D3, the kidneys metabolise this form to the active state, 1,25-dihydroxyvitamin D 
(1,25(OH)2D3), which exerts it’s effects by binding to the vitamin D receptor (VDR) in 
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target tissues (3). 
 





1.3. Functions of Vitamin D  
The main function of Vitamin D is to maintain calcium, phosphorous and bone 
homeostasis. Vitamin D functions to maintain adequate and steady calcium levels in the 
serum. Vitamin D deficiency therefore plays a major role in the pathogenesis of bone 
mineralisation diseases, such as rickets in children, and osteomalacia, osteopaenia, 
osteoporosis and fractures in adults. 
A single vitamin D receptor is responsible for vitamin D hormone functions, and is present 
in the target cells of enterocytes, osteoblasts and renal tubular cells. 
It has recently been recognised that tissues and cells not responsible for regulating calcium 
and phosphate metabolism have specific receptors for 1,25(OH)2D3 . This includes cells of 
the parathyroid gland, skin keratinocytes, colon, ovaries, pituitary gland, promyelocytes 
and lymphocytes. This suggests that the consequences of vitamin D deficiency are not 
limited to bone metabolism alone (4). 
Vitamin D deficiency has been linked to the pathogenesis of many other diseases such as 
hypertension, diabetes mellitus, tumour growth (vis. colon, prostate, breast), autoimmune 
diseases and infections (5). 
1.3.1. Vitamin D and Bone Health 
The most well studied and understood function of vitamin D relates to bone health.        
The most important function of vitamin D is to maintain a steady serum calcium 
concentration. Calcium is essential for many vital processes, some of these include 
myocardial and skeletal muscle contractility, action potential generation and conduction, 
and calcium dependant intracellular second messenger systems. Vitamin D maintains 
calcium levels through three main pathways. Firstly, vitamin D optimises calcium 
absorption from the intestine through active mechanisms. It also acts to absorb phosphate. 
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Without vitamin D, only 10-15% of dietary calcium is absorbed. Secondly, when dietary 
calcium is inadequate, vitamin D acts to maintain steady levels by mobilising calcium from 
bone. Vitamin D, together with parathyroid hormone (PTH), stimulates osteoblasts to 
produce receptor activated nuclear factor-κβ ligand (RANKL), which promotes bone 
resorption by stimulating the formation and activation of osteoclasts. Serum calcium is 
maintained at the expense of bone mineralisation. Lastly, vitamin D increases renal 
calcium absorption. Vitamin D, via stimulation of PTH, increases the absorption of 
calcium from the distal convoluted tubule in the kidney. This is approximately 7g/day, and 
is thus a significant contribution to the serum calcium pool (2). 
If dietary calcium is not available, internal stores, from bone, are utilised. Prolonged 
vitamin D deficiency results in hypocalcaemia and hypophosphataemia. In children, this 
leads to rickets, a deforming bone disease secondary to impaired bone mineralisation. 
Adults develop osteomalacia and osteopaenia, and with time, osteoporosis. The majority of 
these patients are elderly females. The main concern in both adults and children with 
vitamin D deficiency is the risk of bone fractures. In both groups, fractures may cause 
considerable bone pain and often deformity. Fracture healing is frequently slow, with 
significant morbidity and mortality. Patients with fractures frequently have prolonged 
hospital admissions, with associated increased risk of hospital acquired infections such as 
pneumonia, or complications such as heart failure (6). Side effects from osteoporosis 
treatment are common and the economic burden is significant. Many elderly patients die 
prematurely as a result of fractures, particularly that of the hip (7). 
The optimum vitamin D level to prevent fracture is not clear, but most experts agree that it 




1.3.2. Vitamin D and Extra-Skeletal Manifestations 
Biological mechanisms linking vitamin D deficiency with a multitude of non-bone related 
diseases have been proposed for many years. The identification of the 1,25(OH)2D3 
receptor in tissues other than bone (2, 3, 5) have prompted investigation into causal 
relationships between vitamin D deficiency and other disease pathogenesis. Some of the 
better recognised associations are discussed below (Figure 1.2). 
 
Figure 1.2 Vitamin D and extra-skeletal functions (3).  
1.3.2.1. Vitamin D and the Immune System 
One of the most well studied extra–skeletal effects of vitamin D is the interaction between 
vitamin D and the immune system, both the innate and adaptive systems. 
a. The Innate Immune System 
The macrophage expresses the VDR and produces 1,25(OH)2D3 through the synthesis of 
1α-hydroxylase, triggered by interferon γ (IFN γ). The VDR and 1α-hydroxylase gene are 
6 
 
specifically induced when toll-like receptor1/2 (TLR1/2) is activated. This receptor is the 
specific recognition receptor for Mycobacterium tuberculosis (MTB). The TLR1/2-
25(OH)D3 combination stimulates the expression of cathelicidin, an antibacterial protein, 
which promotes killing of MTB and other bacteria. Cathelicidin is also produced by other 
cells, and together with induction of TLR1/2 and high concentrations of 1,25(OH)2D3, is 
able to prime the innate immune response to pathogens (9). 
In addition to this, 1,25(OH)2D3 also enhances the phagocytic action of all dendritic cells, 
promoting pathogen elimination (3). 
This effect of vitamin D on the innate immune response has been shown to reduce 
bacterial, but not viral or fungal, infections. Vitamin D deficiency has been identified as a 
risk factor for tuberculosis in several case control studies (10, 11). 
In southern Africa, tuberculosis is endemic. This is largely due to the Human 
Immunodeficiency Virus/ Acquired Immunodeficiency Syndrome (HIV/AIDS) epidemic. 
It has been noted that African and Indian population groups are at higher risk for 
developing tuberculosis (12). African people generally have lower vitamin D levels (and 
are often vitamin D deficient) due to high skin melanin levels. This may be one of the 
explanations  why this race group is more prone to contracting tuberculosis, and often 
develop a more aggressive form of the disease (3). 
b. The Adaptive Immune System 
T helper 1 (Th1,CD4) and T helper 2 (Th2,CD8) cells are direct targets of 1,25(OH)2D3. 
Once activated, the expression of the VDR on Th1 cells increases 5-fold. 1,25(OH)2D3 acts 
to decrease the proliferation of CD4 cells, therefore decreasing the production of interferon 
gamma (IFNγ), interleukin 2 (IL2) and interleukin 5 (IL5). In contrast, 1,25(OH)2D3 
increases the production of IL4 by CD8 cells, ie. a shift from a Th1, to a Th2 response.  
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In vitamin D deficiency, reduced VDR activation leads to a dampening in the shift from 
Th1 to Th2, and a Th1 response dominates. This may promote the development of 
autoimmune diseases such as multiple sclerosis, Type 1 diabetes mellitus and 
inflammatory bowel diseases such as Crohn’s disease (13). 
1.3.2.2. Vitamin D and Hypertension 
Hypovitaminosis D has been associated with hypertension through its lack of inhibitory 
effects on the renin-angiotensin-aldosterone system (RAAS) (14). A study showed that 
both 25(OH)D3 and 1,25(OH)2D3 were inversely associated with plasma renin and 
angiotensin II concentrations, with 25(OH)D3 deficiency causing augmented renal vascular 
RAAS activity, as well as increased angiotensin II concentrations (15). Later it was shown 
that 1,25(OH)2D3 inhibits renin expression in mice by inhibiting the renin gene expression 
(14). 
It is further postulated that vitamin D has direct affects on the vascular endothelial tone by 
influencing the calcium concentration in the vascular smooth muscle cells. 
Vitamin D may also have a vascular protective effect by reducing the harmful 
consequences of glycation end products on the endothelium, improving activity of the 
nitric oxide (NO) system, and by decreasing atherosclerotic and inflammatory mediators 
(16).  
In addition to this, vitamin D deficiency leads to increases in PTH. High PTH levels may 
increase the blood pressure, as shown during trials of PTH infusion in healthy volunteers 
(1). 
Lower plasma 25(OH)D3 levels in non-obese young women independently predicted the 
odds of subsequently developing hypertension. In another study, Forman et al. (17, 18) 
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reported an association between measured vitamin D deficiency, and increased risk for 
incident hypertension, which was independent of other risk factors. 
Using data from the NHANES III survey (a national survey conducted between January 
1998 and December 1994 from 89 survey locations in the USA), it was found that the 
prevalence of hypertension was significantly higher in those patients with low vitamin D 
levels, with up to 30% of these individuals having hypertension (19). One of few 
prospective studies demonstrated that patients with untreated, mild hypertension who were 
subjected to an artificial UVB source (not UVA) showed a significant reduction in both the 
systolic and diastolic blood pressure (-6/-6 mmHg), as well as a 162% rise in plasma 
25(OH)D3 levels (20). 
A meta-analysis of all data published before November 2013 reported an inverse 
relationship between 25(OH)D3 and hypertension (21). 
In summary, optimal vitamin D levels have beneficial effects on the blood pressure by 
inhibiting the RAAS, modulating vascular tone and indirectly affecting vascular 
endothelium.  
1.3.2.3. Vitamin D and Diabetes Mellitus 
In global reports it has been noted that plasma 25(OH)D3 is a marker of insulin resistance 
in non-diabetic patients, with 25(OH)D3 being inversely associated with fasting glucose, 
fasting insulin, the HOMA-IR index, even when adjusted for other cardiovascular risk 
factors such as obesity and smoking (22). In the SENECA study, no association was found 
between fasting plasma insulin or the HOMA-IR index after adjusting for demographic, 
lifestyle factors and calcium intake. However there was an inverse correlation between 
fasting plasma glucose and the 25(OH)D3 levels (23). A meta-analysis of the effect of 
vitamin D supplementation on glycaemia, insulin resistance and progression to diabetes 
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found that although there was a small improvement on fasting glucose and insulin 
resistance, there was no effect on HBA1C and no improvement in outcome in patients with 
normal fasting glucose. This study concluded that there was no evidence of benefit to 
recommend vitamin D supplementation to improve glycaemic control (24).  
a. Type 1 Diabetes Mellitus 
Type 1 diabetes mellitus is an autoimmune disease, where destruction of β cells by auto-
antibodies in the pancreas leads to progressive insulin deficiency and ultimately β cell 
failure.  
1,25(OH)2D3 has been recognised as an immune-modulator that targets T cells by 
decreasing their recruitment and activation. Furthermore, it has the ability to stimulate 
phagocytes to kill bacteria. Conversely, 25(OH)D3 suppresses the antigen-presenting 
capability of these cells, as well as suppressing important cytokines such as IL12 . 
Phagocytes also produce the enzyme 1 α-hydroxylase which converts vitamin D to its 
active form.   
 1,25(OH)2D3 administration has been shown to be protective against β cell destruction and 
reduces the incidence of both diabetes and insulitis in mice. This seems to be due to a 
predominantly Th2 immune response (shifted from a Th1 response in mice treated with 
1,25(OH)2D3), which reshapes the immune system to increase the elimination of 
autoimmune effector cells (25, 26). 
The efficacy of supplementing 1,25(OH)2D3 after the onset of β cell destruction, in order to 
arrest this progression, is uncertain (26). 
 
b. Type 2 Diabetes Mellitus 
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It has been long known that the β cells in the pancreas express the receptor for 
1,25(OH)2D3. The effector protein for this pathway, calbindin–D28k, is also present in the 
pancreas.  
When comparing vitamin D levels between patients with type 2 diabetes mellitus (T2DM), 
and those without, those with T2DM have lower 25(OH)D3 levels than those without and 
have a higher incidence of vitamin D deficiency. Patients at risk for T2DM  were also 
found to have lower 25(OH)D3 levels (27). 
Studies on animal models have shown that pancreatic insulin secretion is impaired by 
vitamin D deficiency. This is due to loss of calbindin–D28k  β cell protection, which 
protects these cells from cytokine-mediated cell death. However, another factor which 
plays a role in glucose intolerance and insulin resistance in animals with abnormal VDRs is 
the genetic background, as not all animals with VDR knockout develop diabetes mellitus 
(26).  
1,25(OH)2D3 appears to promote insulin release by causing a rise in intracellular calcium, 
via PTH. Low vitamin D increases PTH which may impair glucose tolerance and decrease 
insulin sensitivity. Secondly, vitamin D may enhance insulin responsiveness by stimulating 
the expression of the insulin receptor. Vitamin D’s effect on the immune system, as a 
genetic modulator, is the final mechanism (22). 
The correction of vitamin D deficiency may improve glucose tolerance. However, in the 
case of vitamin D sufficient patients, the supplementation of additional 1,25(OH)2D3  has 
shown conflicting results. Some studies showed improvement in insulin and c-peptide 
secretion, whilst others demonstrated no change. The beneficial effect was, however, 




1.3.2.4. Vitamin D and Dyslipidaemia 
In recent years, the metabolic syndrome (increased waist circumference, 
hypertriglyceridaemia, hypo-HDL-cholesterolaemia, hypertension and high fasting serum 
glucose) has become an increasing problem in many countries worldwide, with reports of 
up to 1 in 5 people having this syndrome (29). Many people have been treated with statins 
as part of the metabolic syndrome management, and it has been noted that those on statins 
have an associated reduced fracture risk (30). It has also been shown that statins may 
improve bone mineral density (31, 32). Another study shows that statins do not affect 
vitamin D status, but rather that low vitamin D levels are associated with dyslipidaemia 
(30). However, it has been shown that patients with replete 25(OH)D3 stores generally 
have better lipograms – lower fasting cholesterol levels, and higher HDL levels, and 
therefore improved cardiovascular risk (29). 
Studies based on vitamin D effects on blood lipids are contradictory (33), and this needs to 
be further investigated.  
In a systematic review by Zittermann et al.,(34)  the influence of vitamin D on serum 
cholesterol levels was not demonstrated.  
The reason for this seems to be due to the anti-atherogenic effects of vitamin D – via 
down-regulation of the renin-angiotensin system, and inhibition of the production of pro-
inflammatory cytokines (29). Another mechanism is reduced expression of mRNA and 
protein levels of plasminogen activator inhibitor-1, and thrombospondin -1, both of which 
are implicated in the pathogenesis of atherosclerosis (30). 
It is also thought that vitamin D increases the activity of lipoprotein lipase by regulating 
adipocytes, and therefore decreases triglyceride levels. 
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In general, there seems to be an inverse relationship between vitamin D levels, and 
components of the metabolic syndrome such as waist circumference, hypertriglyceridaemia 
and hyperglycaemia (35).  
1.3.2.5. Vitamin D and Malignancy 
It has been noted that people exposed to sunlight have lower malignancy rates and 
mortality. This seemingly protective effect was presumed to be as a result of 25(OH)D3 
metabolism by UVB exposure. However, the presence of the VDR in breast, colon, 
prostate and ovarian tissue has prompted further research and an inverse relationship 
between these cancers and vitamin D status has been elicited (36). 
In vitamin D’s role as a genetic-modulator, 1,25(OH)2D3  plays a part in regulating both 
normal and malignant cell growth, differentiation and proliferation.  It also plays an 
important role in apoptosis and induction of terminal differentiation, so that 
hypovitaminosis D may lead to reduced apoptosis and cellular differentiation with resultant 
tumorigenesis (37). 
In addition to these mechanisms, it has been proposed that Vitamin D controls multiple ion 
channels, including calcium and chloride channels, as well as modulating Protein Kinase C 
activity. Low vitamin D levels may lead to impaired control of the above mechanisms and 
lead to lack of inhibition of cell proliferation and differentiation and promote tumour 
growth (38). To illustrate this, the following has been noted: 
1. Sunlight exposure and vitamin D intake were associated with a reduced risk of 
developing breast cancer (39, 40). 
2. Both high and low levels of vitamin D have been implicated as a risk factor for the 
development of prostate cancer (41). 
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3. Many studies have shown a reduction in colorectal cancer risk in patients with 
increased vitamin D intake. However, there are conflicting reports with other 
studies showing no difference for colorectal cancer risk in patients on vitamin D 
supplementation (42, 43).  
1.4. Factors Determining Vitamin D Status 
The human 25(OH)D3 serum concentration is dependent on many factors, namely latitude, 
sun exposure and aging. 
 Latitude and serum 25(OH)D3 concentration has a significant positive correlation in 
Europe. This is because latitude determines the degree of sun exposure. The highest 
prevalence of vitamin D deficiency is in central and southern Europe. The lower levels of 
deficiency in Northern Europe and North American countries (high latitude, low sun 
exposure) has been attributed to the greater consumption of oily fish, as well as dairy 
product vitamin D fortification (44). However, vitamin D levels in countries with high 
degrees of sun exposure have reported higher than expected levels of vitamin D deficiency 
(45-48). At higher and lower latitudes, where sun exposure is far less, the prevalence of 
vitamin D deficiency is even greater (49-51). This is far less surprising than the low levels 
measured in countries closer to the equator. 
Vitamin D levels decline in the elderly (52) and hypovitaminosis D is particularly common 
in post-menopausal women. These lower levels are because aging decreases the ability of 
the human skin to produce vitamin D. Also, the elderly are often confined indoors – 
whether due to illness, reduced mobility or institutionalization (49). Due to reduced 
earning capacity and low pensions, the elderly may also have a diet low in vitamin D and 
may not be able to afford supplementation. 
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With respect to race, definite differences in vitamin D status have been demonstrated. 
Light skinned people generally have higher vitamin D levels than their darker skinned 
counterparts.These differences are due to the fact that people with higher degrees of 
melanin, and therefore pigmentation, with comparable UV light exposure, produce less 
25(OH)D3 than do people with light skins. It is necessary to have these greater levels of 
melanin as the darker skin provides protection from the intensity and amount of sunlight in 
their country of origin (50). It has also been reported that Black people in the USA use less 
dietary supplements than do Whites (53). 
1.5. Global Estimates of Vitamin D Status 
Globally, vitamin D deficiency is widespread, and is emerging as a major health problem. 
One of the main indicators of vitamin D status is sun exposure, which is predicted based on 
latitude (relation to the equator). In countries further north and south, such as Canada, Asia 
and Latin America, lack of sun exposure is considered the major risk factor for deficiency 
(49). Even in countries considered to have high UVB indices, such as parts of Australia 
and the USA, high sunlight exposed states in the USA such as Hawaii and Florida, the 
Middle East and Africa, the levels of hypovitaminosis D is far higher than would be 
expected (46, 47, 51). 
The reasons for this are multi-factorial. In areas with high sun exposure, hypovitaminosis 
D may be due to protective clothing and sunscreen, as well as less time spent outdoors, as a 
result of greater awareness of the risk of skin malignancies. In Muslim countries, covering 
clothing for religious reasons is practiced, resulting in low sun exposure. In Africa, 
pigmentation, from high levels of skin melanin, results in decreased cutaneous synthesis of 
vitamin D3. In fact, Black population groups usually have far lower vitamin D levels than 
their White contemporaries (53). 
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In addition to latitude, seasonal variation in sunlight and outdoor activity levels also plays 
a major role in vitamin D status. In the majority of studies, the highest 25(OH)D3 levels 
were recorded in the summer and autumn months, with the lowest recorded in the winter 
months (45, 54). 
In developing countries, another factor leading to hypovitaminosis D is prolonged 
breastfeeding without vitamin D supplementation to the mother or child, compared to 
infants receiving bottle feeds (49). 
The elderly, hospitalised and institutionalised also commonly have low vitamin D levels – 
this is due to poor dietary levels (little or no fish) as well as little outdoor activity (55). 
Surprisingly, countries with little sunlight exposure such as the Netherlands and 
Scandinavian countries such as Sweden have relatively good 25(OH)D3 levels. It is 
presumed that this is from a diet containing large amounts of oily fish (49). 
1.6. Optimal Vitamin D Status 
There is currently no definition of the optimal vitamin D level (3, 56, 57). The possible 
criteria for which optimal 25(OH)D3 may be defined include that level for which there is:  
1) Maximal suppression of circulating PTH  
2) Maximal absorption of calcium from the gastro-intestinal tract (GIT)                                                              
3) Highest bone mineral density (BMD)                                                                                
4) Lowest rates of bone loss                                                                                                    
5) Reduced rates of falling and reduced incidence of fractures (56)  
These criteria may, however, be problematic as:                                                                                           
1) Serum PTH is only an indirect measure and is not optimally sensitive. Parathyroid 
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hormone is more directly affected by and related to calcium metabolism. Often, an 
individual with deficient vitamin D status may not exhibit a perceptible PTH response (58). 
2) When one compares calcium absorption with vitamin D levels, the lower limits of 
optimal vitamin D sufficiency is difficult to define as calcium absorption initially rises as 
vitamin D rises, but then plateaus at levels >80nmol/l. This makes calcium absorption an 
inefficient marker of serum 25(OH)D3 (57). Also, at ‘normal’ plasma 25(OH)D3 levels, 
calcium absorption varies, so that even at so called current ‘normal’ vitamin D 
concentrations, the calcium absorption is not necessarily optimal. 
3) Reports of higher 25(OH)D3 concentrations correlating with higher BMD have also 
been shown to have non-significant differences in other trials, or to have small positive 
relationships between BMD and 25(OH)D3 (56). 
4) Studies in elderly women indicate that vitamin D supplementation decreases net bone 
loss. The optimum level at which bone loss is minimal remains under debate and has not 
yet been defined (44). 
5) Studies done on the elderly showed a reduction in fall and fracture risk with patients on 
vitamin D supplementation, however again, there is debate as to what the optimal serum 








Table 1.1 Estimates of minimum optimal serum 25(OH)D3 for fracture prevention by 
different authors, adapted from Dawson-Hughes et al. (56). 
Author Optimal 25(OH)D3 level, ng/ml 
Oral vitamin D3 dose needed to reach  
average optimal 25(OH)D3 level 
  
μg/day IU/day 
Lips 20 10-15 400-600 
Holick 30 25 1000 
Heaney 32 40 1600 
Meunier 30 20 800 
Vieth 28 25 1000 
Dawson-Hughes 32 25 1000 
 
The Endocrine Society of America and the International Osteoporosis Foundation suggest 
that a 25(OH)D3 level of 30ng/ml is the optimal lower limit for adequate bone health (60-
61).  
Another concern is whether a 25(OH)D3 level of 30ng/ml is also adequate for vitamin D to 
achieve its extra-skeletal effects, as higher levels than this may be required (4). 
Other markers which have been suggested for estimation of adequate vitamin D status 
include muscle strength, serum calcium and phosphorus levels, bone turnover markers, cell 
proliferation and metabolic function (62). Many of these are impractical, time consuming 
and expensive to perform. In addition to this, optimal levels have only been studied with 
respect to bone health, with little consensus reached on optimal levels or markers with 
regard to the extra-skeletal manifestations of vitamin D deficiency. 
1.7. Measurement of Vitamin D 
Vitamin D status is generally assessed by measuring the 25(OH)D3 level (63). 
Various assays to measure circulating 25(OH)D3 levels have been developed over the 
years. Currently, two of the most widely used assays are a radioiodine-based (RIA) kit, 
18 
 
such as the DiaSorin assay (which is the most widely used assay), and an enzyme 
immunoassay antibody (EIA) type test (64). 
There is an urgent need for standardisation of 25(OH)D3 test assays as variation between 
different methods have made defining optimal vitamin D levels difficult (65). The total 
25(OH)D3 level may be underestimated when vitamin D2 constitutes a large part of the 
total vitamin D level (66). This is most apparent in the EIA method where the primary 
antibody reacts unequally with vitamin D2 and vitamin D3, compared to the DiaSorin assay, 
which does not detect vitamin D2 entirely. Therefore, the RIA based tests have emerged as 
the test of choice for most laboratories (64, 67). This has clinical implications both for the 
detection of hypovitaminosis D, as well as for monitoring of replacement in patients on 
supplementation and vitamin D related disease. 
Binkley et al., (65) sent multiple samples to 6 different laboratories, which all used 
different assays. Results for the same specimens differed by as much as 2-fold. 
Because of this, the International Vitamin D External Quality Assessment Scheme 
(DEQAS) has been monitoring the performance of various assays, and attempts to provide 
information on the accuracy and specificity of these different assays, as well as providing 
an All-Laboratory Trimmed Mean (ALTM) and Standard Deviation (SD) for each method. 
The overall accuracy of the different methods can then be assessed from the percentage 
bias of the method mean from the ALTM (66). 
In addition to the RIA and EIA tests, mass spectrometry is able to measure 25(OH)D3 
accurately, and to distinguish between vitamin D2 and vitamin D3. Until recently, mass 
spectrometry has been used only in research laboratories due to the complexity of the 
analysis. Because mass spectrometry may be a more sensitive and specific test for vitamin 
D analysis, has less inter-laboratory variation than the RIA and EIA tests, as well as being 
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able to independently distinguish between the various forms of vitamin D, it is now 
starting to be routinely used in laboratories around the world (68).   
1.8. Confounding Vitamin D Measurements: Underestimation of  25(OH)D3 
The differences between different assay methods have been discussed in the section above, 
however another cause of underestimation of 25(OH)D3 needs to be highlighted. 
Studies suggest that patients who are obese or who have non-alcoholic steatohepatitis 
(NASH) have significantly lower vitamin D concentrations than age-matched controls.  
This, however, is not as a result of decreased sun exposure, or enhanced production of the 
active 1,25(OH)2D3 metabolite, but rather because vitamin D is a fat soluble pro-hormone. 
This means that it gets deposited in body fat compartments and stored in adipose tissue, 
such as subcutaneously, as well as in the liver in obese patients. This means that there is 
decreased bioavailability of vitamin D3 and assays performed in obese patients, or those 
with NASH, may show erroneously low levels.  Some studies have demonstrated a >50% 
decreased bioavailability of cutaneously synthesised vitamin D3 (70). 
25(OH)D3 level may also be affected by an age-related decline in renal function (59). 
Inducers of the cytochrome P450 system in the liver, such as anti-epileptic drugs (71), 
rifampicin (tuberculosis treatment) (72), as well as anti-retrovirals such as efavirenz (73) 
(the latter two are especially important in the South African setting) promote the 
metabolism of 25(OH)D3 to less biologically active analogs. Again, patients who are 
taking these, and other cytochrome P450 inducers, may have lower vitamin D levels and 
may require higher doses of supplementation (3). 
In addition to this, the season that the test was performed may have important implications 
for 25(OH)D3 estimation. It has been suggested that a 25(OH)D3 level performed in the 
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spring or autumn months may be the best indication of average of 25(OH)D3 over a one 
year period (74). 
More than 85-90% of vitamin D in serum is bound to vitamin D-binding protein, with a 
further 10-15% being bound to albumin. This renders <1% of free circulating vitamin D 
available to act on target cells, and measurements of 25(OH)D3 may therefore be 
erroneously low. Between race groups, genetic polymorphisms for vitamin D-binding 
protein change the affinity of the binding protein for vitamin D, and may partially explain 
the racial differences in levels of total 25(OH)D3 (75). 
1.9. Recommended Vitamin D Dietary Intake 
Vitamin D is uniquely synthesised in the skin and as such there is variation in synthesis 
due to the seasonality of the sun exposure, the degree of skin pigmentation, individual 
genetic factors, use of sunscreen, latitude of area of living and amount of outdoor activity. 
Because of this, recommended dietary intakes (RDIs) are advised based on an assumption 
of minimal or no sun exposure. The RDIs are based on the amount of vitamin D required 
for good bone health (76). 
On average, for adequate bone health, it is advised that adult males and females should 
receive 600IU/d of vitamin D to correspond with a serum 25(OH)D3 level of 20ng/ml. 
Males and females over the age of 71yr should have 800IU/d of vitamin D, to correspond 
to the same serum level of 25(OH)D3. The upper limit for vitamin D supplementation is 
4000IU/d (76). 
The determinants of the upper limits of RDI for vitamin D include evidence of a U-shaped 
relationship for mortality from cardiovascular disease, certain cancers, falls and fractures, 




Therefore, the upper limit of RDI is not a target intake, but rather advises at what levels 
risk for harm begins to increase. 
 
1.10. Supplementation of Vitamin D as Prophylaxis 
Despite the association between hypovitaminosis D and multiple skeletal and extra-skeletal 
diseases, the therapeutic window for beneficial, positive effects from vitamin D 
supplementation is narrow. This is due to the potential for toxicity with supplementation. 
These include mainly calcaemic effects such as bone demineralisation and hypercalcaemia, 
which may result in hypercalciuria and renal failure from nephrocalcinosis or renal stones. 
These effects are usually only seen with massive doses of vitamin D >10 000IU/d, 
however caution should be taken not to exceed the recommended daily allowance (76). 
Excess sunlight exposure does not result in vitamin D toxicity. This is because excess 
precholecalciferol will photoisomerise into the biologically inactive photoisomers 
lumisterol and tachysterol. Another efficient sunscreen is melanin, which reduces the 
efficiency of sun-mediated photosynthesis of precholecalciferol. This explains why Black 
people have lower circulating levels of 25(OH)D3 compared to Caucasians (5). In addition 
to this, the 24-hydroxylase pathway will breakdown excess vitamin D2 and D3, and 








1.11. Aims of the Study 
1. To investigate the overall status of vitamin D levels in a northern suburbs practice in 
Johannesburg, Gauteng. 
2. To describe the vitamin D status in different age, gender and race groups.  
3. To assess for any possible correlation between the vitamin D level and cholesterol level, 
glucose level, hypertension, diabetes mellitus and HOMA-IR index. 
4. To describe seasonal variation of vitamin D levels.   
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2. Chapter 2.   Patients and Methods 
2.1. Patients 
This study was a cross-sectional, retrospective, descriptive study involving review of 
patient records. Patient data was collected from files from a private practice in the northern 
suburbs of Johannesburg. 
A random sample of 1000 files from patients attending this practice from December 2010 
until December 2012 was collected. Only data from patients living in the greater 
Johannesburg area was captured, and no exclusions were made based on age, race, gender 
or reason for consultation. 
Ethics approval was obtained for this study (M120957) (Appendix A). 
2.2. Methods 
Data collected included the patient’s age, race, gender, basal pre-supplement 25(OH)D3 
level (ng/ml), as well as the date the test was performed, fasting glucose level (mmol/l), 
fasting cholesterol level (mmol/l), HOMA-IR score, and whether or not the patient had 
known, pre-existing history of diabetes mellitus (no distinction was made for Type 1 or 
Type 2) or hypertension. Also documented was the suburb of residence. 
Data was further grouped into the following categories: 
Age - 
 Youth : <17 years old 
 Young Adult : 18 – 25 years old 
 Adult : 26 – 65 years old 










 Abnormal >2 
 Normal ≤2 
Cholesterol: 
 Hypercholesterolaemia >5mmol/l 
 Normal ≤5mmol/l 
Area of Residence: 
 North – Parktown, Randburg, Fourways, Sandton 
 South – Lenasia, Alberton, Vereeniging, Vaal Triangle 
 East – Boksburg, Benoni, Germiston, Bedfordview 
 West – Krugersdorp, Roodepoort 
 Pretoria – Midrand, Pretoria 
Season (according to the World Meteorological Organisation, for South Africa): 
 Summer – 22 December – 19 March 
 Autumn – 20 March – 20 June 
 Winter – 21 June – 22 September 
 Spring – 23 September – 21 December 
Data was captured onto an Excel spread sheet for further analysis. 
 
2.3. Laboratory Analyses 
All patient blood samples were drawn before 10h00 and were performed under fasting 
conditions, after a minimum 8 hour fast.  
The 25(OH)D3 testing was performed using a Diasorin assay and the laboratory specific 
levels were used as reference ranges (Lancet Laboratories). 
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The reference ranges for 25(OH)D3 :  
 Normal >30ng/ml 
 Moderate Deficiency = 10-29.9ng/ml 
 Severe Deficiency <10ng/ml 
Cholesterol and glucose levels were tested using an enzymatic method. 
HOMA-IR score - Fasting Insulin X Fasting Glucose 
          22.5 
This was used to indicate insulin resistance. 
 
2.4. Statistical Methods 
Descriptive statistics were used to describe the sample in terms of: 25(OH)D3 level, age, 
gender, race, fasting glucose level, fasting cholesterol level, HOMA-IR index, 
hypertension and diabetes mellitus. Frequencies for these variables were calculated, as well 
as mean 25(OH)D3 levels for each group. Differences in means between independent 
samples were tested by using Student’s t test or oneway analysis of variance (ANOVA). 
The Chi- squared test was performed to determine if the difference in mean vitamin D 
levels between variables was statistically significant. Correlation and regression testing 
was performed using the Pearson Correlation test. The limit for statistical significance was 




3. Chapter 3.  Results 
3.1. Demographics of the Study Population 
Of the 1000 subjects, 71.4% were female. The majority of subjects were White in ethnicity 
(75.8%), and were between the ages of 26-65 years (83.2%). Forty percent of patients lived 
in the Northern suburbs, with the remainder residing in the rest of Johannesburg and 



























   
Race   
   Black  (n=24) 8 (0.8%) 16 (1.6%) 
   Indian (n=218) 66 (6.6%) 152 (15.2%) 
   White  (n=758) 212 (21.2%) 546 (54.6%) 
   
Age   
   Youth   (n=27) 12 (1.2%) 15 (1.5%) 
   Young Adult (n=97) 27 (2.7%) 70 (7%) 
   Adult    (n=832) 230 (23%) 602 (60.2%) 
   Elderly (n=44) 17 (1.7%) 27 (2.7%) 
   
Suburb   
   North    (n=400) 107 (10.7%) 293 (29.3%) 
   South    (n=202) 57 (5.7%) 145 (14.5%) 
   East       (n=138) 39 (3.9%) 99 (9.9%) 
   West      (n=88) 20 (2%) 68 (6.8%) 
   Pretoria (n=172) 63 (6.3%) 109 (10.9%) 
   
Hypertension 





   
Diabetes Mellitus 





      





Table 3.2 Three way table of 25(OH)D3, gender and age
 
Gender and Age 


























Severe Deficiency 1 (7%) 11 (16%) 51 (8%) 6 (22%) 0 2 (7%) 11 (5%) 0 
Moderate Deficiency 8 (53%) 40 (57%) 398 (66%) 12 (44%) 9 (75%) 18 (67%) 164 (71%) 12 (71%) 
Normal 6 (40%) 19 (27%) 153 (26%) 9 (33%) 3 (25%) 7 (26%) 55 (24%) 5 (29%) 
 
  
Table 3.3 Three way table of 25(OH)D3, age and race
 
Age and Race 










































































































3.2. Vitamin D Status According to Sub-Group 
The mean 25(OH)D3 level for the study population was 24.45ng/ml (SD11.81). According 
to the laboratory specific reference ranges, this is classified as moderate deficiency.  
Overall, 74.3% of subjects were 25(OH)D3 deficient, with 8.2% being severely deficient 
(Table 3.4). 
Of particular note, three quarters (75.5%) of male subjects were vitamin D deficient, of 
which 71% were moderately deficient. 9.7% of the females, compared to 4.5% of males, 
had severe vitamin D deficiency, although there was no statistically significant difference 
between mean vitamin D levels between the gender groups. 
In the race category, 69.3% of the White subjects were 25(OH)D3 deficient, of which 22 
(3%) were over the age of 65years. This is compared to 83.4% of Black subjects, and a 
staggering 90.8% of Indian subjects who were 25(OH)D3 deficient. Again, in both groups, 
the majority of these subjects were in the adult category. Interestingly, none of the Indian 
subjects in the youth category had a normal 25(OH)D3 level (n = 11) (Table 3.3). 
Although there was no significant difference between 25(OH)D3 means and deficiency 
categories between different age groups (p = 0.745 and p = 0.149), it is interesting to note 














There was no statistically significant difference in 25(OH)D3 levels between different 
gender and age groups (p=0.597 and p=0.149 respectively). 
There was however statistically significant differences between 25(OH)D3 levels between 
different race groups (p=0.001), suburb of residence (p=0.034), and those patients having 
hypertension (p=0.007), diabetes mellitus(p=0.037), hypercholesterolaemia (p=0.001) and 
a HOMA score >2 (p=0.001). 
There was also a statistically significant difference between mean 25(OH)D3 levels 
measured in different seasons – with the highest means being measured in the summer 






3.3. Vitamin D Mean 
Table 3.4 Prevalence of Vitamin D Deficiency by Gender, Age, Race, Suburb,                   














Deficiency        
(<10ng/ml) 
P value 
     
Total (n=1000) 
 
257 (25.7%) 661 (66.1%) 82 (8.2%)  
     
Gender     
   Male (n=286)               70 (24.5%) 203 (71%) 13 (4.5%)                
0.017 
   Female (n=714)  187 (26.2%) 458 (64.1%) 69 (9.7%) 
     
Race     
   Black (n=24) 4 (16.6%) 18 (75%) 2 (8.4%)                 
0.001    Indian (n=218) 20 (9.2%) 139 (63.8%) 59 (27%) 
   White (n=758) 233 (30.7%) 504 (66.5%) 21 (2.8%) 
     
Age     
   Youth (n=27)  9 (33.3%) 17 (63%) 1 (3.7%)                  
0.149 
   Young Adult (n=97) 26 (26.8%) 58 (60%) 13 (13.2%) 
   Adult (n=832) 208 (25%) 562 (67.5%) 62 (7.5%) 
   Elderly (n=44) 14 (31.8%) 24 (54.6%) 6 (13.6%) 
     
Suburb     
   North (n=400) 112 (28%) 265 (66.3%) 23 (5.7%)               
0.034 
   South (n=202) 45 (22.2%) 128 (63.4%) 29 (14.4%) 
   East (n=138) 36 (26.1%) 93 (67.4%) 9 (6.5%) 
   West (n=88) 25 (28.3%) 58 (66%) 5 (5.7%) 
   Pretoria (n=172) 39 (22.7%) 117 (68%) 16 (9.3%) 
     
Hypertension  






14 (9.5%)              
 
0.354 
     
Diabetes Mellitus 






9 (13.2%)                
 
0.219 
     
HOMA                  
   >2 (n=193) 32 (16.6%) 139 (72%) 22 (11.4%)             
0.003 
   <2 (n=341) 98 (28.7%) 220 (64.5%) 23 (6.8%) 
     
CHOL                  
   >5 (n=434) 88 (20.3%) 306 (70.5%) 40 (9.2%) 
0.001 
   <5 (n=384) 123 (32%) 231 (60.2%) 30 (7.8%) 
     
GLUCOSE     
   >7 (n=26) 3 (11.5%) 20 (77%) 3 (11.5%) 0.265 
   <7 (n=832) 211 (25.4%) 551 (66.2%) 70 (8.4%) 
     
SEASON     
   Summer (n=227) 82 (36%) 136 (60%) 9 (4%)               
0.005 
   Autumn (n=256) 56 (21.8%) 184 (71.8%) 16 (6.4%) 
   Winter (n=373) 68 (18.2%) 258 (69.2%) 47 (12.6%) 




There was no statistically significant difference in mean 25(OH)D3 levels between gender 
and age groups (p = 0.597 and p = 0.745 respectively). Similarly, there was no significant 
difference between mean 25(OH)D3 levels between patients who have diabetes mellitus    
(p = 0.087) and between different suburbs of residence (p = 0.069). There was, however, 
statistically significant differences between the mean 25(OH)D3 levels between different 
race groups (p = 0.001), those who had hypercholesterolaemia (p = 0.001), and those who 
had a HOMA-IR index >2 (p = 0.001). As BMI may be strongly associated with T2DM, 
insulin resistance (HOMA-IR index) and hypercholesterolaemia, and BMI was not one of 
the variables measured, the negative correlation between vitamin D status and 
hypercholesterolaemia may become insignificant should BMI be corrected for. It is worth 
noting that although there was a significant difference between mean 25(OH)D3 between 
those patients who had hypertension and those who did not (p = 0.007), the absolute mean 
25(OH)D3 level differed only marginally: 22.03 ng/ml in those with hypertension, and 
24.87ng/ml in those without. 
Although mean serum 25(OH)D3 levels in diabetic and non-diabetic patients was different, 
this was insignificant (p = 0.087) in this study. However, there was a significant difference 
between fasting glucose levels and mean 25(OH)D3 levels, with those patients with fasting 
glucose >7mmol/l having lower 25(OH)D3 means (p = 0.016). There was no significant 
correlation between fasting glucose and 25(OH)D3 level (correlation co-efficient -0.467,    
p = 0.432). Moreover, with insulin resistance, there were similar findings, those patients 
with high HOMA-IR indices (>2) had lower serum 25(OH)D3 levels (p = 0.001). 
Mean 25(OH)D3 levels taken during different seasons was also statistically significant       
(p = 0.001), with the highest mean 25(OH)D3 being measured during the summer months, 





















3.4. Correlation and Regression Testing 












MEAN 25(OH)D  
 
24.45 (11.81)  
 
GENDER 
   Male (n=286) 








   Black (n=24) 
   Indian (n=218) 







0.001– Indian vs. White 
 
AGE 
   Youth (n=27) 
   Young Adult (n=97) 
   Adult (n=832) 











   East (n=400) 
   North (n=202) 
   Pretoria (n=138) 
   South (n=88) 
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   No  (n=932) 
 






    <2 (n=193) 
    >2 (n=341) 
 
25.89 (11.88) 





   <5mmol/l (n=384) 








   <7mmol/l (n=832) 








   Summer (n=189) 
   Autumn (n=155) 
   Winter (n=476) 















The possibility of a correlation between 25(OH)D3 and variables such as age, cholesterol 
level, glucose level and HOMA level was investigated. 
 With increasing age, there was no significant change in 25(OH)D3, no correlation was 
found (r = 0.0017, p = 0.958 ). There was a negative correlation between 25(OH)D3 and 
cholesterol levels (r = -0.187, p = 0.001). Similarly, there was a negative correlation 
between 25(OH)D3 levels and the glucose level (r = -0.118, p = 0.001). There was also a 
slight negative correlation between 25(OH)D3 levels and the HOMA-IR level (r = -0.096,  



























































































Vitamin D Correlation with Age Vitamin D Correlation with Cholesterol 




Using regression testing, the estimated change in variable levels was investigated      
(Tables 3.6 and 3.7). When measured using univariate regression testing, there were 
statistically significant changes in cholesterol levels, glucose levels and the HOMA-IR 
indices. In all cases, the higher the 25(OH)D3 level was, the more optimal these levels 
were. 
However, when investigated using multivariate regression testing, these differences were, 
in most cases, statistically insignificant. 
The effect of changes in 25(OH)D3 levels on the subjects’ clinical characteristics revealed 
that only cholesterol showed a statistically significant inverse relationship (coefficient -
0.028, p = 0.001). As the 25(OH)D3 level increases, so the cholesterol levels decrease, and 
become more optimal. In addition to this, backward stepwise regression models were used. 
This did not demonstrate any other significant relationships. 
The effects of changes in the subjects’ clinical characteristics on the 25(OH)D3 level was 
also examined. Again, there was a statistically significant negative correlation between the 
cholesterol level and the 25(OH)D3 level (coefficient -1.022, p = 0.001). An inverse 
relationship was also noted between different race groups and the 25(OH)D3 (coefficient -
8.357, p = 0.001). Again, although backward stepwise regression models were performed, 










Table 3.6 Regression analysis of the effect of the subjects’ clinical characteristics on the 
25(OH)D3 level 
 Univariate Multivariate 
 Coefficient P value Coefficient P value 
Cholesterol -0.052 0.001 -1.022 0.001 
Glucose -0.041 0.001 -0.467 0.432 
HOMA-IR -0.025 0.035 -0.309 0.282 
Age -0.009 0.791 +0.029 0.492 
Race -0.335 0.001 -8.357 0.001 
Gender -0.034 0.382 -1.302 0.234 
Hypertension -0.070 0.161 -0.838 0.588 





Table 3.7 Regression analysis of the effect of the 25(OH)D3 level on the subjects’ clinical 
characteristics 
 Univariate Multivariate 
 Coefficient P value Coefficient P value 
Cholesterol -0.522 0.001 -0.028 0.001 
Glucose -0.192 0.001 -0.004 0.256 
HOMA-IR -0.338 0.035 -0.011 0.121 
Age -0.007 0.791 +0.086 0.077 
Hypertension -0.028 0.161 -0.001 0.584 








4. Chapter 4.  Discussion 
In this study, a strikingly high incidence of vitamin D deficiency among patients attending 
a practice in the northern suburbs of Johannesburg was observed. This is consistent with 
worldwide reports of high levels of hypovitaminosis D. To my knowledge, this is the first 
study to assess vitamin D status in a random cohort in South Africa (not related to specific 
or bone related diseases), as well as with respect to related health correlates and patient 
characteristics. 
In this study, there was no overall difference between mean vitamin D levels between 
males and females or different age groups. In addition, there was also no correlation 
between gender or age and vitamin D levels. This differs from other studies where females 
had lower levels, and higher incidence of vitamin D deficiency, compared to males (44, 49, 
54, 78). This has been reported as being particularly common in postmenopausal women, 
as many studies indicate a higher level of hypovitaminosis D amongst the elderly (44, 49, 
54). The difference in vitamin D status between age groups was not demonstrated in this 
study. Possibilities for this may be: firstly, as the practice from which this study was 
performed is in an affluent region of the city, the elderly subjects were more likely to be 
retired, and probably able to spend more time in outdoor pursuits such as gardening, golf, 
walking etc. Secondly, a less likely possibility is that some of these patients may have 
already been on vitamin D supplementation, in the form of over the counter vitamins, or 
prescriptions from previous doctors, which they did not disclose to the physician at the 
time of consultation. However, when considering these results one should also take into 
consideration the fact that there were very small numbers in especially the youth and 




There was a significant difference between vitamin D means measured between different 
race groups. The lowest levels were recorded amongst those population groups with darker 
skins, ie. Black and Indian. Again, this is consistent with other studies (49, 53, 54). 
Cultural practices with respect to clothing are another factor related to the low vitamin D 
levels, demonstrated particularly in the Indian group. Many Muslims wear covering 
clothing such as a veil (hijab or niqab), and long sleeves and dresses, covering almost the 
entire body. This practice greatly diminishes the skin’s synthesizing ability (77). This study 
shows similar differences between vitamin D levels between race groups as do other 
worldwide reports. 
A significant difference between mean 25(OH)D3 levels due to seasonal variance was 
observed. The highest means were recorded during the summer months, and the lowest 
during the winter months. This is expected as the highest sun exposure (UVB index) and 
outdoor activity rates are during the longer daylight hours experienced in the summer 
months. This correlation is noted in most vitamin D status studies (47, 49, 51, 78)(47, 49, 
51, 78). 
This study demonstrated a significant difference between vitamin D levels between 
specifically the northern and southern suburbs of Johannesburg. The lowest levels were 
recorded in the south, and the highest in the north. As the municipality of Lenasia was 
included in the southern suburbs, and given that the majority of the subjects’ data collected 
from this area were Indian, this difference in vitamin D levels was presumed to be on the 
basis of the cultural and ethnic differences – greater skin melanin and pigmentation, 
protective and covering clothing for religious and cultural reasons, rather than on an area/ 
regional basis. Johannesburg covers an area of 1645km
2 
(Wikipedia), and as such the 
degree of UVB exposure difference is considered negligible. 
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There was a significant difference between mean vitamin D levels between subjects who 
had underlying hypertension, and those who did not. Patients with hypertension had lower 
mean 25(OH)D3 levels.  
Although this study showed that the mean 25(OH)D3 level was significantly lower in those 
subjects with hypertension compared to those without, it did not demonstrate the negative 
correlation suggested by the previously mentioned studies and meta-analysis. 
No significant correlation was found in this study between vitamin D levels between 
subjects who had diabetes mellitus and subjects who did not. In addition, no significant 
difference was found between mean vitamin D status between subjects with well controlled 
glucose levels and those with high glucose levels. Since the numbers of subjects in these 
groups were small, perhaps a significant correlation may have been found if the numbers 
were larger. 
Of note in this study, a significant correlation was found between the 25(OH)D3 level and 
the cholesterol level, as well as a significant difference in mean 25(OH)D3 between 
subjects with hypercholesterolaemia and those without. The reason for this is unclear and 
should be further investigated.  
4.1. Study Limitations 
As this was a retrospective study, some variables which may have had an influence on the 
bioavailability of vitamin D were not available to be captured. These include factors such 
as: 
1. The body mass index (BMI) of each individual. 
2. Presence of NASH. 
3. The renal function – specifically a decline in renal function. 
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3. The presence of a cytochrome P450 inducing drug, such as an anti-epileptic, anti-
retroviral, or rifampicin. However, the contribution from these drugs was presumed to be 
small as less than 5 patients had epilepsy, only 2 were HIV positive, and none were known 
to have active tuberculosis, or to be on rifampicin. 
A further limitation to this study was that the numbers of young (n = 27) and elderly (n = 
47) patients was relatively small. The demographic profile of South Africa was not 
representative in this study, as Black patients made up only 2.4% (n = 24) of the cohort. 
In terms of co-morbid diseases, there was a small number of patients with hypertension (n 
= 147) and diabetes mellitus (n = 68). In addition, no distinction between T1DM and 
T2DM was made, as the number of patients with this disease was very small. Although no 
correlation was found in this study, a correlation may exist should the numbers have been 
bigger. 
In addition, only patients with a pre-existing history of diabetes mellitus or hypertension 
were captured. Because of this, there may have been a number of patients with 
undiagnosed disease in this cohort. Furthermore, the vitamin D status was not correlated to 





5. Chapter 5.  Conclusion 
This study demonstrates that a significant majority of subjects were vitamin D deficient. 
The demographics of this vitamin D deficient population are in keeping with similar 
studies around the world. The major variable which was out of keeping with worldwide 
reports was that in this study, the elderly did not have significantly lower serum 25(OH)D3 
compared to other age groups. Furthermore, there was no difference noted between serum 
vitamin D levels between males and females.  
Risk factors for vitamin D deficiency, as from the results of this study in the Johannesburg 
region were: 
 Indian ethnicity 
 Residence in the southern suburbs (Lenasia) 
 A fasting cholesterol >5mmol/l 
 A fasting glucose >7mmol/l 
 A HOMA-IR index >2 
 25(OH)D3 level taken in the winter months. 
This group is a representative sample of the White and Indian populations living in 
Johannesburg and gives a reasonable indication of the state of vitamin D levels in these 
groups in Johannesburg as a whole, and may be stratified to predict the status of vitamin D 
in the rest of the people living in Johannesburg. One may expect similar levels of 
deficiency despite this city’s high UVB index. 
Given the high incidence of hypovitaminosis D in this population, it would be interesting 
to follow these subjects up over their lifetimes to document the 25(OH)D3 trend over many 
40 
 
years  as well as the incidence of especially bone disease, but also possible extra-skeletal 
manifestations such as diabetes mellitus, hypertension and malignancy.  
5.1. The Way Forward 
Given that hypovitaminosis D is re-emerging as a global pandemic, and with the evidence 
that this is also a concern in South Africa, the future requires the focus to be placed on the 
following areas: 
1. For the public: 
a. Awareness of the existence and extent of the problem 
b. Education on the complications and consequences of vitamin D deficiency 
c. Education on how to prevent deficiency 
d.  South African guidelines as to who should be tested for deficiency 
2. For the Practitioner: 
a. South African guidelines on who to screen for deficiency 
b. Training on interpretation of results 
c. South African guidelines as to vitamin D supplementation: dose and when 
to prescribe 
3. For the laboratory / Endocrine advisory society: 
a. Emphasis on the importance of assay standardisation 
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